Christine Hann

Assistant Professor

19982018
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Small Cell Lung Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
HhAntag691 Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Camptothecin Medicine & Life Sciences
Type I DNA Topoisomerase Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2018

Metformin
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Drug Therapy

Lung and Thymic Carcinoids

Hann, C. & Forde, P., Sep 1 2018, In : Endocrinology and Metabolism Clinics of North America. 47, 3, p. 699-709 11 p.

Research output: Contribution to journalReview article

Carcinoid Tumor
Ectopic Hormones
Multiple Endocrine Neoplasia
Thymus Neoplasms
Lung

NCCN guidelines® insights: Small cell lung cancer, version 2.2018 featured updates to the NCCN guidelines

Kalemkerian, G. P., Loo, B. W., Akerley, W., Attia, A., Bassetti, M., Boumber, Y., Decker, R., Dobelbower, M. C., Dowlati, A., Downey, R. J., Florsheim, C., Ganti, A. K. P., Grecula, J. C., Gubens, M. A., Hann, C., Hayman, J. A., Heist, R. S., Koczywas, M., Merritt, R. E., Mohindra, N. & 11 othersMolina, J., Moran, C. A., Morgensztern, D., Pokharel, S., Portnoy, D. C., Rhodes, D., Rusthoven, C., Santana-Davila, R., Williams, C. C., Hoffmann, K. G. & Hughes, M., Oct 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 10, p. 1171-1182 12 p.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Guidelines
Disease Management
Immunotherapy
Signs and Symptoms

Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer

Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., Long, L., Diao, L., Wang, J., Bensman, Y., Hurtado, B., de Groot, P., Sulman, E. P., Wistuba, I. I., Chen, A., Fleisher, M. & 4 othersHeymach, J. V., Kris, M. G., Rudin, C. M. & Byers, L. A., Aug 10 2018, In : Journal of Clinical Oncology. 36, 23, p. 2386-2394 9 p.

Research output: Contribution to journalArticle

temozolomide
Small Cell Lung Carcinoma
Placebos
Disease-Free Survival
Survival